MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Argos Therapeutics Company Profile (NASDAQ:ARGS)

Consensus Ratings for Argos Therapeutics (NASDAQ:ARGS) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $17.25 (182.79% upside)

Analysts' Ratings History for Argos Therapeutics (NASDAQ:ARGS)
Show:
DateFirmActionRatingPrice TargetActions
7/16/2015Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/26/2015FBR & Co.Initiated CoverageOutperform$19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2015MLV & Co.Set Price TargetBuy$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/18/2015Roth CapitalReiterated RatingBuy$21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/19/2015MLV & Co.Reiterated RatingBuy$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/31/2015MLV & Co.Reiterated RatingBuy$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/26/2015Roth CapitalInitiated CoverageBuy$21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2015MLV & Co.Initiated CoverageBuy$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/19/2014Stifel NicolausInitiated CoverageBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/4/2014Stifel NicolausInitiated CoverageBuy -> Buy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/4/2014Piper JaffrayInitiated CoverageOverweight$18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/4/2014JMP SecuritiesInitiated CoverageOutperform$17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/4/2014Needham & Company LLCInitiated CoverageBuy$17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 8/2/2013 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha